Premium Only Content
![cas: 2489876-37-9 GMB-475 GMB475 factory](https://1a-1791.com/video/s8/6/E/a/h/B/EahBh.OvCc.1.jpg)
cas: 2489876-37-9 GMB-475 GMB475 factory
cas: 2489876-37-9 GMB-475 GMB475 factory
CBNumber: CB05494743
Chemical Name: GMB-475 GMB475
Molecular Formula: C43H46F3N7O7S
Formula Weight: 861.94
CAS No.: 2489876-37-9
GMB-475 is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1 protein and recruit the E3 ligase Von Hippel-Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.
GMB-475 induces rapid proteasomal degradation and inhibition of downstream biomarkers, such as STAT5 in both human CML K562 cells and murine Ba/F3 cells expressing BCR-ABL1. GMB-475 inhibits the proliferation of certain clinically relevant BCR-ABL1 kinase domain point mutants and further sensitizes Ba/F3 BCR-ABL1 cells to inhibition by imatinib, while demonstrating no toxicity toward Ba/F3 parental cells
GMB 475 is a BCR-ABL1 kinase PROTAC® Degrader. Induces degradation of BCR-ABL1 and cABL1, inhibits downstream STAT5 signaling and suppresses cell proliferation in chronic myeloid leukemia cells lines.
Chronic myeloid leukemia is a myeloproliferative disorder characterized by the presence of the oncogenic fusion protein BCR-ABL1. ABL1, one of the fusion partners in the BCR-ABL1 protein, contains an allosteric myristoylation binding site. Especially, the proteolysis targeting chimera (PROTAC) technology provides a unique toolkit for probing the non-kinase roles of proteins in a cellular context without resorting to genetic modification of the system. Particularly, PROTACs are heterobifunctional molecules that recruit an E3 ligase to a target protein. In this study, George M. Burslem, et al further investigate the potential of a new series of PROTACs, utilizing an allosteric inhibitor (GNF-5) to degrade BCR-ABL1 protein.
ABL1 tyrosine kinase inhibitors (TKIs) effectively reduce kinase activity and downstream signaling of BCR-ABL1. George M. Burslem, et al developed a series of PROTACs. In particular, PROTACs allosterically target BCR-ABL1 protein and recruit the E3 ligase Von Hippel Lindau (VHL). Consequently, this effect results in ubiquitination and subsequent degradation of the oncogenic fusion protein. Typically, the lead compound is GMB-475. Moreover, in both human CML K562 cells and murine Ba/F3 cells expressing BCR-ABL1, GMB-475 induces rapid proteasomal degradation and inhibition of downstream biomarkers. Notably, GMB-475 inhibits the proliferation of certain clinically relevant BCR-ABL1 kinase domain point mutants. Importantly, GMB-475 reduces viability and increases apoptosis in primary chronic myeloid leukemia CD34+ cells, with no effect on healthy CD34+ cells. Furthermore, GMB-475 degrades BCR-ABL1 and reduces cell viability in primary chronic myeloid leukemia stem cells.
-
LIVE
The Dan Bongino Show
2 hours agoFollowing The Money In This Growing Scandal (Ep. 2419) - 02/10/2025
158,026 watching -
LIVE
The Rubin Report
43 minutes ago'Real Time' Crowd Roars for Bill Maher’s Brutal Message to Democrats
3,901 watching -
LIVE
Steven Crowder
2 hours ago🔴 How Donald Trump Murdered Cancel Culture at the Super Bowl
53,400 watching -
2:11:05
Matt Kohrs
9 hours agoThe Chaotic Trading Week Ahead! || The MK Show
19.3K4 -
LIVE
Caleb Hammer
54 minutes agoFinancial Infidelity EXPOSED Right Before Marriage | Financial Audit
162 watching -
LIVE
LFA TV
21 hours agoAUDIT THE WHOLE GOVERNMENT! | LIVE FROM AMERICA 2.10.25 11am
5,047 watching -
LIVE
Rethinking the Dollar
46 minutes agoMonday Morning Check-In: Trump Cancels Penny & Ron Joins DOGE
353 watching -
43:13
BonginoReport
5 hours agoSuper Bowl Vibe Shift: Trump Cheered, Taylor Swift Booed (Ep.136) - 02/10/2025
104K135 -
LIVE
Wendy Bell Radio
6 hours agoThe Rats Are Scrambling
13,006 watching -
1:26:34
Jeff Ahern
3 hours ago $1.60 earnedMonday Madness with Jeff Ahern( put a fork in them)
22.8K4